Background: Current evidence on the incidence and outcomes of patients with thyroid storm in the United States is limited to single-center case series. This study determined the national incidence of thyrotoxicosis with and without thyroid storm and clinical outcomes among hospitalized patients during a 10-year period in the United States.
Methods: Retrospective longitudinal analysis was conducted of clinical characteristics, mortality, hospital length of stay, and costs from 2004 to 2013. Adults (≥18 years of age) with a primary diagnosis of thyrotoxicosis with and without thyroid storm were included. To determine the incidence, outcomes, and cost of thyrotoxicosis with and without thyroid storm, the study used data from the National Inpatient Sample database, the largest public inpatient database, with a representative sample of all non-federal hospitals in the United States.
Results: Among 121,384 discharges with thyrotoxicosis during the study period (M ± standard error = 48.7 ± 0.11 years; 51.9% Caucasian; 77.3% female), 19,723 (16.2%) were diagnosed with thyroid storm. During the past decade, the incidence of thyroid storm ranged between 0.57 and 0.76 cases/100,000 U.S. persons per year, and 4.8 and 5.6/100,000 hospitalized patients per year. Thyroid storm was associated with significantly higher hospital mortality (1.2-3.6% vs. 0.1-0.4%, p < 0.01) and longer length of stay (4.8-5.6 vs. 2.7-3.4 mean days, p < 0.001) compared to patients with thyrotoxicosis without storm. Inflation-adjusted hospitalization costs progressively increased in patients with thyroid storm from $9942 to $12,660 between 2004 and 2013 (p < 0.01).
Conclusions: One of every six discharges for thyrotoxicosis was diagnosed with thyroid storm. Thyroid storm is associated with a 12-fold higher mortality rate compared to thyrotoxicosis without storm. The incidence and mortality of thyroid storm has not substantially changed in the past decade. However, hospitalization costs have significantly increased.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916241 | PMC |
| http://dx.doi.org/10.1089/thy.2018.0275 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors.
Nat Rev Endocrinol
January 2025
Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Immune-related adverse events (irAEs), including endocrine irAEs, can occur in response to cancer immunotherapy using immune checkpoint inhibitors (ICIs). Of the endocrine irAEs, pituitary and thyroid irAEs are most frequently observed, followed by primary adrenal insufficiency, type 1 diabetes mellitus and hypoparathyroidism. Notably, pituitary irAEs and type 1 diabetes mellitus can be lethal if overlooked, potentially leading to adrenal crisis and diabetic ketoacidosis, respectively.
View Article and Find Full Text PDFThyroid Storm Management: Beta-1 Selective or Propranolol?
Crit Care Med
January 2025
All authors: Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
A clinical challenge: delayed diagnosis of autoimmune polyglandular syndrome type II in a patient with thyroid eye disease.
Orbit
January 2025
Department of Ophthalmology and Visual Sciences, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
A 35-year-old woman with thyroid eye disease (TED) was found to have autoimmune polyglandular syndrome type II (APS-II) 1 year after developing symptoms of this rare syndrome, during which she underwent 8 emergency department visits before receiving a targeted endocrinology workup. Thyroid disease is the second most common autoimmune syndrome associated with APS-II after primary adrenal insufficiency. Identification of this syndrome is critical as it can be life-threatening if left untreated.
View Article and Find Full Text PDFCerebral Venous Sinus Thrombosis as a Unique Initial Presentation of Thyroid Storm.
Neurologist
January 2025
Public Health, Khamis Mushayt General Hospital, Khamis Mushait, Saudi Arabia.
Introduction: Thyrotoxicosis is associated with a hypercoagulable state, increasing the risk of thrombotic events like CVST. Literature review reveals thyroid hormone's role in promoting prothrombotic abnormalities, impacting coagulation factors and platelet function.
Case Report: This study explores the rare occurrence of thyroid storm complicated by deep cerebral venous sinus thrombosis (CVST) in a young male with no prior history of thyroid disease.
A Narrative Review of the Role of Blood Biomarkers in the Risk Prediction of Cardiovascular Diseases.
Cureus
December 2024
Public Health Sciences, Scientific Knowledge for Ageing and Neurological Ailments (SKAN) Research Trust, Bengaluru, IND.
Article Synopsis
- Cardiovascular disease (CVD) is a major global health issue, making it essential to find biomarkers that can detect it early in healthy people to enhance preventive measures and improve overall health outcomes.
- Various biomarkers, such as atherogenic lipoproteins and inflammatory markers like C-reactive protein (CRP), have shown connections to CVD risk factors, aiding in risk prediction when combined with traditional indicators.
- Emerging biomarkers like myeloperoxidase (MPO) and procalcitonin (PCT) are being explored for their potential in early detection of systemic infections, emphasizing the importance of identifying the best biomarker combinations for effective diagnosis and risk assessment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!